A problematic pattern of using cocaine, amphetamines, or related stimulants, leading to significant impairment or distress.
Medically reviewed by
Dr. Mihaela G.
Stimulant Use Disorder covers problematic patterns of use involving cocaine, amphetamines, methamphetamine, and related stimulant substances, all sharing the same eleven diagnostic criteria used across substance use disorders in this manual, differing primarily in their specific pharmacological profile, typical route of use, and certain practical aspects of treatment.
What unites these substances clinically is their action on the brain’s dopamine reward system, producing intense, rapid euphoria and energy that, for many users, becomes a powerful driver of repeated use, often considerably more rapidly than with substances having a slower or less intense reward profile. This speed and intensity of reinforcement is part of why stimulant use disorders, once established, can be particularly difficult to interrupt, even when a person clearly recognizes the harm being caused.
A genuinely important and sometimes counterintuitive feature of this category is the absence of an FDA-approved medication for treating the use disorder itself, distinguishing stimulants from alcohol and opioids, where specific pharmacological treatments exist. This makes behavioral treatment the cornerstone of care here in a way that’s somewhat different from how some other substance use disorders are approached.
Impaired control over use
Using more or for longer than intended, persistent desire or unsuccessful efforts to cut down, and spending significant time obtaining, using, or recovering from stimulant effects.
Social and functional impairment
Continued use despite interpersonal or occupational problems, giving up important activities, and recurrent use in physically hazardous situations.
Risky use and craving
Continued use despite knowledge of physical or psychological harm, and intense craving, often described as particularly powerful with stimulants compared to some other substances.
Tolerance and withdrawal
Needing markedly increased amounts for the same effect, and a withdrawal syndrome marked predominantly by fatigue, low mood, and increased sleep, the “crash” that follows stimulant use, quite different in character from the agitation-predominant withdrawal seen with some other substances.
Pattern of use
Often characterized by binge patterns, using repeatedly over a compressed period until supply or physical capacity is exhausted, followed by a “crash” period of exhaustion and low mood.
⋅ Intense craving, often described as particularly powerful and difficult to resist
⋅ Significant low mood, irritability, or anxiety during the “crash” following use
⋅ Anxiety or paranoia, particularly with heavy or sustained use
⋅ Emotional blunting or depression during periods of abstinence
⋅ Persistent preoccupation with obtaining or using the substance
⋅ Impaired judgment, particularly during periods of intoxication or binge use
⋅ Difficulty concentrating during withdrawal or the “crash” period
⋅ Paranoid thinking, particularly with heavy, sustained use
⋅ Tolerance, requiring increasing amounts for the same effect
⋅ Significant fatigue and increased sleep during withdrawal (“crash”)
⋅ Cardiovascular strain connected to stimulant effects, including elevated heart rate and blood pressure
⋅ Weight loss connected to appetite suppression during periods of heavy use
⋅ Binge patterns of use followed by a crash period of exhaustion
⋅ Continued use despite clear social, occupational, or health consequences
⋅ Giving up important activities in favor of using
⋅ Using in hazardous situations or combining with other substances
Cocaine use disorder has a 12-month prevalence of approximately 0.2-0.4%, and amphetamine-type stimulant use disorder around 0.2%, with rates varying considerably by region depending on availability and local patterns of use.
Risk factors include a family history of substance use disorders, co-occurring mental health conditions (particularly ADHD, for which stimulant misuse can sometimes begin from diverted prescription medication), significant life stress or trauma, and social or occupational environments where stimulant use is more normalized or accessible.
Comorbidity with other substance use disorders, particularly alcohol and opioids, is substantial, and co-occurring mental health conditions including depression, anxiety, and ADHD are notably elevated in this population.
Stimulant Use Disorder develops through the interaction of neurobiological, genetic, and environmental factors, with the dopamine reward system playing a particularly central, well-characterized role.
Direct dopamine system action distinguishes stimulants from many other substances; cocaine and amphetamines directly increase dopamine availability in reward circuitry, producing an intense, rapid reinforcement signal that drives repeated use considerably faster, for many people, than substances with a less direct or intense reward profile.
Neuroadaptation with repeated use leads to changes in dopamine receptor sensitivity and reward circuit function, contributing to tolerance, the intensity of craving, and the characteristic depressive “crash” that follows stimulant use as the brain’s reward system temporarily depletes and adjusts.
Genetic factors contribute to individual vulnerability, with twin studies suggesting a meaningful heritable component to stimulant use disorder risk specifically.
Co-occurring conditions, particularly ADHD, represent a notable risk pathway; some individuals begin using stimulants, sometimes diverted prescription medication, to self-manage attention difficulties, which can progress to a genuine use disorder, particularly with non-prescribed, higher-dose, or different-route use than appropriately prescribed treatment.
Stimulant Use Disorder is diagnosed based on a problematic pattern of use leading to clinically significant impairment or distress, evidenced by at least two of eleven criteria within a 12-month period, mirroring the structure used across substance use disorders: using more or longer than intended, persistent desire or unsuccessful efforts to cut down, significant time spent obtaining/using/recovering, craving, recurrent failure to fulfill role obligations, continued use despite interpersonal problems, giving up important activities, recurrent hazardous use, continued use despite physical/psychological problems, tolerance, and withdrawal. Severity is specified as mild (2-3 criteria), moderate (4-5), or severe (6 or more), and the specific substance (amphetamine-type, cocaine, or other) is identified.
Differential diagnosis requires distinguishing this from appropriately prescribed stimulant medication use for a diagnosed condition like ADHD, where use as directed doesn’t constitute a use disorder, though misuse beyond prescribed parameters can. Stimulant-induced psychotic or anxiety symptoms should be assessed and distinguished from independent psychiatric conditions, given how commonly heavy stimulant use can produce these symptoms directly.
Stimulant Use Disorder treatment relies predominantly on behavioral approaches, given the absence of an FDA-approved medication specifically for the use disorder itself.
Contingency management
This approach, providing tangible incentives for verified abstinence, has the strongest evidence base specifically for stimulant use disorders, often outperforming other approaches in controlled research.
Cognitive-behavioral therapy
CBT addressing triggers, craving management, and relapse prevention strategies is a core, well-evidenced component of comprehensive treatment.
The Matrix Model
A structured, integrated treatment approach combining individual counseling, group therapy, family education, and relapse prevention, specifically developed for stimulant use disorders, has solid supporting evidence.
Addressing comorbid ADHD
When underlying, undertreated ADHD appears to be a contributing factor, appropriately managed treatment for ADHD, under careful medical supervision given the complexity of prescribing stimulant medication in this context, can be an important part of a comprehensive plan.
No specific approved medication
Despite considerable research effort, no medication has received FDA approval specifically for stimulant use disorder, making consistent engagement with behavioral treatment the central pillar of care, alongside management of any co-occurring mental health conditions.
Engage with contingency management or structured behavioral programs if available. These have the strongest evidence specifically for stimulant use disorders and provide concrete, motivating structure during recovery.
Anticipate the “crash” period and plan for it. Significant fatigue and low mood following use, or during early abstinence, is expected and temporary, not necessarily a sign of a separate, worsening depression, though it should still be monitored and discussed with a provider.
Get evaluated for underlying ADHD if attention difficulties are part of your history. If stimulant use began as self-management of untreated symptoms, appropriately supervised treatment for the underlying condition can be an important part of your recovery plan.
Build structure around the binge-crash cycle if this describes your pattern. Identifying specific triggers for binge episodes and having a concrete plan for high-risk moments supports more sustainable change.
Address any co-occurring depression or anxiety directly. Given high rates of comorbidity, treating these conditions alongside the substance use pattern tends to support better, more durable outcomes.
The prognosis for Stimulant Use Disorder with appropriate, sustained behavioral treatment is genuinely favorable, and contingency management in particular has solid evidence for supporting meaningful periods of abstinence and reduced use.
Without treatment, the disorder tends to follow a chronic, relapsing course, with significant cardiovascular, psychological, and social consequences accumulating over time with sustained heavy use.
Comorbid ADHD, depression, or anxiety, when present, generally benefit from direct, concurrent treatment, and addressing these alongside the substance use pattern tends to improve overall outcomes.
Seek evaluation if stimulant use, whether cocaine, amphetamines, or another stimulant, is causing problems with relationships, work, health, or finances, or if attempts to cut down have been unsuccessful.
Seek evaluation for underlying ADHD if attention difficulties predate or seem connected to your stimulant use pattern, since appropriately managed treatment may be an important part of addressing the underlying issue.
Seek urgent medical attention for chest pain, irregular heartbeat, or severe agitation connected to stimulant use, given the genuine cardiovascular risks these substances carry, particularly with heavy or sustained use.
Someone in your life might be quietly looking for this. Share it:
These conditions share overlapping symptoms and are often misdiagnosed.
Despite considerable research effort, no medication has received FDA approval specifically for treating stimulant use disorder. This makes behavioral treatment, particularly contingency management and cognitive-behavioral therapy, the central pillar of care for this condition, somewhat different from alcohol or opioid use disorder, where specific approved medications exist alongside behavioral approaches.
The crash refers to a period of significant fatigue, low mood, and increased sleep that follows stimulant use, particularly after a binge episode. This reflects the brain’s reward system temporarily depleting and adjusting after the intense dopamine activation stimulants produce. It’s part of the recognized withdrawal pattern for this substance category, and understanding it as an expected, temporary phase can help people navigate it without assuming something else is wrong.
When taken as prescribed for a diagnosed condition, stimulant medication use doesn’t constitute a use disorder. However, misuse beyond prescribed parameters, higher doses, different routes of administration, or use without a prescription, can progress to a genuine stimulant use disorder. Some people who develop this disorder began by self-managing undiagnosed attention difficulties, which is why evaluating for underlying ADHD is often a relevant part of comprehensive assessment.
Contingency management is a structured behavioral approach providing tangible incentives, such as vouchers or small rewards, for verified abstinence from the substance. It has the strongest evidence base specifically for stimulant use disorders, often outperforming other treatment approaches in controlled research, possibly because it provides an immediate, concrete reinforcement that can help counterbalance the intense reward stimulants themselves provide.
Ciketic, S., Hayatbakhsh, M. R., Doran, C. M., Najman, J. M., & McKetin, R. (2012). A review of psychological and pharmacological treatment options for methamphetamine dependence. Journal of Substance Use, 17(4), 363–383. PubMed
AshaRani, P. V., Hombali, A., Seow, E., Ong, W. J., Tan, J. H., & Subramaniam, M. (2020). Non-pharmacological interventions for methamphetamine use disorder: a systematic review. Drug and Alcohol Dependence, 212, 108060. PubMed
Lee, N. K., & Rawson, R. A. (2008). A systematic review of cognitive and behavioural therapies for methamphetamine dependence. Drug and Alcohol Review, 27(3), 309–317. PubMed
Higgins, S. T., Sigmon, S. C., Wong, C. J., Heil, S. H., Badger, G. J., Donham, R., Dantona, R. L., & Anthony, S. (2003). Community reinforcement therapy for cocaine-dependent outpatients. Archives of General Psychiatry, 60(10), 1043–1052. PubMed
Volkow, N. D., Koob, G. F., & McLellan, A. T. (2016). Neurobiologic advances from the brain disease model of addiction. New England Journal of Medicine, 374(4), 363–371. PubMed
